Patents-Review.com
ClassID:

109108 ⎘

C12N15/864 - CPC Classification

Classification description:

Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression; Vectors or expression systems specially adapted for eukaryotic hosts for animal cells; Viral vectors Parvoviral vectors, e.g. parvovirus, densovirus

Recent Application in this class:
#1
20240167002
2024-05-23

Compositions and Methods for Producing Recombinant AAV

 #2
20230277428
2023-09-07

Changing Eye Color by Gene Transduction

 #3
20230265459
2023-08-24

Compositions Useful in Treatment of Spinal Muscular Atrophy

 #4
20220313585
2022-10-06

Changing eye color by gene transduction

 #5
20220186251
2022-06-16

VIRAL VECTORS FOR THE TREATMENT OF DIABETES

 #6
20220056090
2022-02-24

AAV-EPO FOR TREATING COMPANION ANIMALS

 #7
20220031778
2022-02-03

Method of reducing neuronal microtubule binding protein Tau (Tau) levels

 #8
20210220247
2021-07-22

Changing eye color by gene transduction

 #9
20200405845
2020-12-31

Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

 #10
20200283739
2020-09-10

Compositions and methods for producing recombinant AAV

 #11
20200056205
2020-02-20

Compositions useful in treatment of spinal muscular atrophy

 #12
20190321463
2019-10-24

SCALABLE MANUFACTURING PLATFORM FOR VIRAL VECTOR PURIFICATION AND VIRAL VECTORS SO PURIFIED FOR USE IN GENE THERAPY

 #13
20190030188
2019-01-31

Method for genetic treatment using the AAV-XBP1s/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis

 #14
20180265893
2018-09-20

Viral vectors for the treatment of diabetes

 #15
20180251508
2018-09-06

AAV-EPO for treating companion animals

 #16
20180135074
2018-05-17

RECOMBINANT AAV VECTORS FOR GENE THERAPY OF HUMAN HEMATOPOIETIC DISORDERS

 #17
20170362608
2017-12-21

Compositions and methods for the production of scAAV

 #18
20160206706
2016-07-21

Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

 #19
20130252325
2013-09-26

Duplexed parvovirus vectors

 #20
20130072548
2013-03-21

Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

 #21
20130066402
2013-03-14

Engineered red-shifted channelrhodopsin variants

 #22
20120183573
2012-07-19

Intracellular viral vector delivery method employing iron ion/viral vector composite

 #23
20100310516
2010-12-09

Duplexed parvovirus vectors

 #24
20070110724
2007-05-17

Duplexed parvovirus vectors